Evommune's stock fell sharply in pre-market activity, sliding 16.4% to $10.93 after the company disclosed that EVO756, its oral MRGPRX2 antagonist, did not meet primary or secondary endpoints in a Phase 2b trial for atopic dermatitis.
The Palo Alto-based clinical-stage biotechnology company said the randomized, double-blind, placebo-controlled study enrolled 121 adults with moderate-to-severe atopic dermatitis and evaluated outcomes over a 12-week treatment period. The company reported that EVO756 failed to achieve the study's primary and secondary endpoints at any dose tested.
Following the result, Evommune stated it will not advance EVO756 in atopic dermatitis. The company indicated it still intends to proceed with Phase 2b development of the same compound in migraine prophylaxis, where a newly initiated study is underway.
This atopic dermatitis outcome represents the second consecutive Phase 2b failure for EVO756 in 2026. Earlier this year, the compound missed its primary endpoint in a chronic spontaneous urticaria clinical trial, prompting Evommune to halt that program entirely. The back-to-back setbacks have materially reduced near-term prospects for EVO756 across inflammatory indications.
With the atopic dermatitis program shelved, Evommune's nearer-term pipeline value now centers on two assets: EVO301, described by the company as an IL-18 binding protein fusion candidate currently in Phase 2b development for both atopic dermatitis and ulcerative colitis, and the migraine prophylaxis trial for EVO756 that the firm has chosen to continue.
Analyst reaction was mixed. Evercore ISI maintained its Buy rating on Evommune stock following the announcement, even as broader analyst sentiment has been split in recent weeks.
The broader U.S. equity market offered little support for risk assets in pre-market trade. The S&P 500 was down about 0.2%, the Dow Jones Industrial Average off roughly 0.3%, and the Nasdaq declined near 0.5%. Market participants were described as cautious amid rising oil prices tied to U.S.-Iran tensions, elevated Treasury yields, and upcoming inflation releases, with key CPI and PPI readings due later in the week.
The combination of a binary clinical trial failure in a closely watched indication, the precedent of an earlier chronic spontaneous urticaria setback, and a generally risk-off market environment intensified selling pressure on Evommune shares. The drop pushed the stock toward its 52-week low of $10.47 and reversed much of the post-disappointment recovery the company had been experiencing.
Clear summary
Evommune reported that EVO756 missed primary and secondary endpoints in a Phase 2b atopic dermatitis trial of 121 patients over 12 weeks, prompting the company to abandon that indication while continuing development in migraine. This is the second Phase 2b failure for EVO756 in 2026, shifting near-term pipeline value to EVO301 and the migraine study and contributing to a sharp pre-market stock decline to $10.93.